Naveris, Inc

Website http://www.naveris.com

Founded 2017

Employees 4

Overview

Naveris uses proprietary technology to develop blood tests to detect viral cancers, which comprise 25% of human cancers. Our initial goal is to target HPV+ cancers with a high unmet clinical need, which also have a path to rapid adoption/reimbursement and next develop tests for all viral cancers. We provide blood test kits to physicians and analyze patient blood samples to quantify their viral tumor burden.

Management Team

Co-Founder, Chairman & CEO

Piyush Gupta

President & Chief Scientific Officer

Philip Stephens

Dr. Stephens is an expert in next-generation sequencing and cancer genome analysis who brings a breadth of experience in life sciences and the clinical diagnostics and laboratory industries. Dr. Stephens was Chief Scientific Officer at Foundation Medicine Inc (FMI) for nearly 8 years where he oversaw the development and commercialization of FMI's comprehensive cancer genomics diagnostic tests.

Laboratory Director

Stephen P Naber

Dr. Naber was Chief of Pathology from 2002-2015 and serves as an Associate Chair in the Department of Pathology at Tufts University School of Medicine. Dr. Naber also previously directed Tufts's clinical laboratory and has been the recipient of National Institutes of Health and Department of Defense grants and awards for studies in studies of breast neoplasia, models of tumor development, and regulation of gene expression in human breast cancer.

Chief Clinical Officer

Barry Berger, MD FCAP

Dr. Berger was the Chief Medical Officer for Exact Sciences Corporation, developer of the Cologuard DNA test for colorectal cancer screening. He is boarded in Anatomic, Clinical & Cytologic pathology. Most of his clinical career was spent at the Dept of Pathology and Lab Medicine of Harvard Pilgrim Healthcare [Chairman (1988-1999), Assoc Director (1982-1988)]. He has served on the Medicare Evidence Development and Coverage Advisory Comm. (2015).

Co-founder

PHILIP HAYDON

Dr. Haydon is the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. He is an internationally recognized leader in the study of neuron-glial interactions in disease and a repeat entrepreneur who has co-founded multiple biotech companies.

SVP of Business Operations & Finance

Tommy Liem

Mr. Liem was at Thomas H. Lee Partners for seven years where he managed financial reporting, portfolio monitoring, and operations initiatives and was an integral part of the firm’s fundraising efforts. He has over 20 years of experience running finance and business operations at companies such as Nuance Communications, State Street Corporation, Fidelity Investments, The MathWorks Inc, Percussion Software, The World Bank & The Hackett Group.